Intravascular Stents Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Drug Eluting Stents, Bare Metal Stents, Bioabsorbable Stents), By Product (Coronary Stents, Peripheral Stents), By End-Use (Hospitals & Clinics, Ambulatory Surgical Centers, Others), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 13.22 Billion
CAGR (2026-2031)	7.39%
Fastest Growing Segment	Hospitals & Clinics
Largest Market	North America
Market Size (2031)	USD 20.28 Billion

Market Overview

The Global Intravascular Stents Market will grow from USD 13.22 Billion in 2025 to USD 20.28 Billion by 2031 at a 7.39% CAGR. Intravascular stents are expandable mesh tubes designed to be implanted into narrowed or obstructed arteries to restore blood flow and maintain vessel patency. The market is primarily driven by the globally aging population and the rising incidence of cardiovascular diseases which necessitate frequent interventional procedures to manage coronary artery disease and other vascular conditions. According to the European Society of Cardiology, in 2024, cardiovascular disease accounted for over 3 million deaths annually across its member countries, highlighting the persistent and critical demand for effective therapeutic devices.

However, the market faces a substantial challenge due to stringent regulatory frameworks governing product approval and safety standards. Regulatory authorities enforce rigorous clinical testing requirements that extend development timelines and elevate costs for manufacturers before a device can reach the commercial stage. Additionally, the potential for product recalls due to adverse events such as thrombosis can severely impact brand reputation and delay market adoption for new technologies.

Key Market Drivers

The escalating global prevalence of cardiovascular diseases serves as the primary catalyst for the intravascular stents market, directly increasing the volume of angioplasty procedures required to manage arterial obstructions. As sedentary lifestyles and poor dietary habits become more common, the incidence of coronary artery disease continues to rise, necessitating mechanical intervention to restore blood flow. According to the Centers for Disease Control and Prevention, September 2025, in the 'Vital Statistics Rapid Release' report, heart disease remained the leading cause of death in 2024, accounting for 683,037 deaths in the United States alone. This persistent burden of disease ensures a sustained demand for therapeutic devices as healthcare systems strive to manage the mortality associated with vascular conditions. Furthermore, major industry players report consistent revenue growth in this sector; according to Medtronic, June 2025, in the 'Fiscal Year 2025 Annual Report', their Cardiovascular Portfolio generated $12.5 billion in net sales, reflecting the critical and ongoing need for cardiovascular interventions globally.

Technological advancements in stent design and materials constitute the second major driver, as manufacturers introduce next-generation devices that improve patient outcomes and expand the treatable patient pool. Innovations such as bioresorbable scaffolds and drug-eluting technologies have significantly reduced the risks of restenosis and thrombosis compared to earlier bare-metal iterations. These enhancements allow physicians to treat more complex lesions and peripheral vascular conditions that were previously difficult to manage with older technologies. For instance, continuous investment in R&D is yielding high-growth returns for leading manufacturers. According to Abbott, January 2025, in the 'Fourth-Quarter and Full-Year 2024 Results' press release, the Medical Devices segment grew 13.7% in the fourth quarter, driven partially by a surge of over 20% in Structural Heart revenue which leverages advanced scaffold technologies. Such product evolution encourages healthcare providers to upgrade their inventory, thereby sustaining market momentum and revenue expansion.

Download Free Sample Report

Key Market Challenges

The stringent regulatory frameworks governing product approval and safety standards represent a primary challenge impeding the growth of the Global Intravascular Stents Market. Regulatory authorities globally enforce rigorous clinical testing and quality assurance requirements that manufacturers must satisfy before a device can be commercialized. These comprehensive mandates significantly extend the product development lifecycle and increase the financial burden on companies, often diverting capital away from research and development activities. This complex environment delays the entry of innovative stent technologies and restricts their availability in key regions.

According to MedTech Europe, in 2024, the average time to certification for medical devices under the new regulatory landscape extended to between 13 and 18 months, while compliance costs surged by approximately 100% compared to previous directives. Such delays and escalated expenditures force manufacturers to reconsider their market strategies, often leading to the discontinuation of legacy products or the deprioritization of markets with high regulatory hurdles. Consequently, the slow pace of approval directly hampers market expansion and limits the immediate accessibility of advanced therapeutic solutions for patients with cardiovascular conditions.

Key Market Trends

The shift toward Ambulatory Surgical Centers (ASCs) for stent procedures is fundamentally altering the procurement landscape, driven by evolving reimbursement policies and the need for cost-effective healthcare delivery. Healthcare systems are increasingly diverting percutaneous coronary interventions (PCIs) from hospital settings to outpatient facilities to alleviate inpatient capacity constraints and reduce procedural costs. This migration is supported by regulatory updates, such as the expansion of CMS covered procedure lists, which incentivize providers to perform catheter-based interventions in these lower-cost environments. Consequently, stent manufacturers are adapting their supply chain strategies to cater to the specific inventory and logistical needs of smaller, high-volume outpatient centers. According to HST Pathways, March 2025, in the 'State of the Industry Report', cardiology accounted for 24% of total ASC block time utilization in 2024, reflecting the rapid prioritization of vascular interventions within these facilities.

Simultaneously, the incorporation of artificial intelligence in stent sizing and selection is revolutionizing pre-procedural planning by enhancing the precision of device deployment. Advanced algorithms are now integrated with intravascular imaging technologies, such as Optical Coherence Tomography (OCT), to automate the analysis of vessel dimensions and lesion characteristics. This technological leap addresses the critical challenge of stent malapposition and underexpansion, which are leading causes of device failure and restenosis. By leveraging machine learning to process complex imaging data, clinicians can select the optimal stent size and landing zone with unprecedented accuracy, thereby improving long-term clinical outcomes. According to the National Institutes of Health, July 2025, in the 'Harnessing Artificial Intelligence in Interventional Cardiology' review, deep learning algorithms demonstrated a 94% accuracy in predicting incomplete stent expansion, underscoring the potential of these tools to minimize procedural errors.

Segmental Insights

The Hospitals and Clinics segment currently represents the fastest-growing category within the global intravascular stents market due to the rising prevalence of cardiovascular conditions requiring complex procedural intervention. This expansion is largely attributed to the availability of specialized catheterization laboratories and critical care units within these facilities which are essential for ensuring patient safety during stent placement. Furthermore, established reimbursement frameworks from authorities such as the Centers for Medicare and Medicaid Services frequently favor inpatient settings for these procedures. Consequently, the ability of hospitals to effectively manage high procedural volumes continues to drive substantial segmental development.

Regional Insights

North America maintains a leading position in the global intravascular stents market due to a high prevalence of cardiovascular diseases and advanced healthcare infrastructure. The region benefits from the strong presence of major medical device manufacturers and favorable reimbursement policies that support patient access to essential treatments. Furthermore, the U.S. Food and Drug Administration plays a critical role in maintaining rigorous safety standards, which fosters clinical confidence in new product approvals. This combination of regulatory stability, high healthcare spending, and widespread adoption of interventional procedures secures North America’s status as the primary regional market.

Recent Developments

• In June 2024, Boston Scientific announced a definitive agreement to acquire Silk Road Medical for a purchase price of $27.50 per share, representing an enterprise value of approximately $1.16 billion. Silk Road Medical is recognized for its Transcarotid Artery Revascularization (TCAR) procedure and the ENROUTE Transcarotid Stent System, which provides a minimally invasive solution for stroke prevention in patients with carotid artery disease. This strategic acquisition significantly expands the company’s vascular portfolio by incorporating a clinically differentiated stent technology that has been shown to reduce the risk of stroke and surgical complications compared to traditional open surgery.
• In June 2024, Elixir Medical announced that the U.S. FDA granted Breakthrough Device Designation for its DynamX Sirolimus-Eluting Coronary Bioadaptor System. This novel implant is designed to treat symptomatic ischemic heart disease by unlocking and separating its helical strands after the vessel heals, thereby restoring natural vessel pulsatility and compliance. Unlike conventional fixed stents that permanently cage the artery, the bioadaptor aims to improve coronary luminal diameter and reduce plaque progression by allowing normal hemodynamic modulation. The designation acknowledges the potential of this unique adaptive technology to provide more effective treatment for patients with coronary artery disease.
• In April 2024, Abbott announced that the U.S. Food and Drug Administration (FDA) approved the Esprit BTK Everolimus Eluting Resorbable Scaffold System. This breakthrough device is the first dissolvable stent of its kind approved in the United States for the treatment of chronic limb-threatening ischemia in arteries below the knee. The system is designed to keep the vessel open and deliver a therapeutic drug to support healing before completely dissolving over approximately three years. The approval was based on the results of the LIFE-BTK clinical trial, which showed superior patency and reduced disease progression compared to the standard balloon angioplasty.
• In February 2024, Biotronik announced the CE mark certification and subsequent launch of the Freesolve Resorbable Magnesium Scaffold for the treatment of coronary artery lesions. This third-generation device uses a proprietary magnesium alloy designed to provide robust vessel support while achieving approximately 99 percent magnesium resorption within twelve months of implantation. The company highlighted that the scaffold offers deliverability and performance comparable to permanent metallic drug-eluting stents but with the advantage of eventually leaving the vessel implant-free to restore natural vasomotion. The launch was supported by clinical data from the BIOMAG-I trial, which demonstrated favorable safety and efficacy outcomes.

Key Market Players

• Boston Scientific Corporation
• Medtronic plc.
• Terumo Medical Corporation
• Abbott Laboratories Inc.
• BIOTRONIK SE & Co. KG
• Stryker Corporation
• Microport Scientific Corporation
• Stentys S.A.
• HELLMAN & FRIEDMAN LLC
• B. Braun SE

By Type	By Product	By End-Use	By Region
Drug Eluting Stents Bare Metal Stents Bioabsorbable Stents	Coronary Stents Peripheral Stents	Hospitals & Clinics Ambulatory Surgical Centers Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Intravascular Stents Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Intravascular Stents Market, By Type:

• Drug Eluting Stents
• Bare Metal Stents
• Bioabsorbable Stents

• Intravascular Stents Market, By Product:

• Coronary Stents
• Peripheral Stents

• Intravascular Stents Market, By End-Use:

• Hospitals & Clinics
• Ambulatory Surgical Centers
• Others

• Intravascular Stents Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE